Raid Aljumaily to Carboplatin
This is a "connection" page, showing publications Raid Aljumaily has written about Carboplatin.
Connection Strength
0.068
-
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019 10 01; 30(10):1613-1621.
Score: 0.041
-
Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer. Lung Cancer. 2014 Jan; 83(1):67-72.
Score: 0.027